Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. April 2015 16:01 ET | Quelle: Lisata Therapeutics

NeoStem Announces First Patient Randomized in Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

NEW YORK, April 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the randomization of...
27. April 2015 07:30 ET | Quelle: Lisata Therapeutics

NeoStem's Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From the European Medicines Agency

NEW YORK, April 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the European...
20. April 2015 07:30 ET | Quelle: Lisata Therapeutics

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma

NEW YORK, April 20, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the expansion of...
09. April 2015 07:30 ET | Quelle: Lisata Therapeutics

NeoStem Announces Extension of Study Under Grant From California Institute of Regenerative Medicine (CIRM) to Fund Research of Retinal Disease

NEW YORK, April 9, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today the extension of its...
06. April 2015 07:30 ET | Quelle: Lisata Therapeutics

NeoStem to Present at Multiple April Conferences

NEW YORK, April 6, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based personalized medicine therapies, announced...
16. März 2015 06:00 ET | Quelle: Lisata Therapeutics

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

NEW YORK, March 16, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today the presentation of...
12. März 2015 07:30 ET | Quelle: Lisata Therapeutics

NeoStem to Present at Two Upcoming Investor Conferences in March

NEW YORK, March 12, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced...
05. März 2015 07:30 ET | Quelle: Lisata Therapeutics

NeoStem PreSERVE AMI Clinical Trial One-Year Results to be Presented at American College of Cardiology Annual Scientific Session on March 15

NEW YORK, March 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based personalized medicine therapies, announced...
02. März 2015 16:01 ET | Quelle: Lisata Therapeutics

NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update

NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based personalized medicine therapies, announced...
05. Februar 2015 17:17 ET | Quelle: Lisata Therapeutics

NeoStem to Present at BIO CEO & Investor Conference and at Sachs Associates Cancer Bio Partnering & Investment Forum

NEW YORK, Feb. 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced...

Vorherige Seite

Nächste Seite